J. Davignon

发表

Apolipoprotein E polymorphism and atherosclerosis.

C. Sing, R. Gregg, J. Davignon, 1988, Arteriosclerosis.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

D. Gaudet, B. McCrindle, R. Hegele, 2014, The Canadian journal of cardiology.

The cardioprotective effects of statins

J. Davignon, 2004, Current atherosclerosis reports.

The lipid hypothesis. Pathophysiological basis.

J. Davignon, 1978, Archives of surgery.

Role of Endothelial Dysfunction in Atherosclerosis

P. Ganz, J. Davignon, Peter Ganz, 2004, Circulation.

Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease.

R. Krauss, H. Campos, J. Davignon, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Emphasis on pleiotropic effects, a new paradigm shift?

J. Davignon, 2004, Coronary artery disease.

CHARACTERIZATION OF A NEW LCAT MUTATION CAUSING FAMILIAL LCAT DEFICIENCY (FLD) AND THE ROLE OF APOE AS A MODIFIER GENE OF THE FLD PHENOTYPE

L. Bernier, M. Tremblay, R. Dufour, 2009 .

Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype.

L. Bernier, M. Tremblay, R. Dufour, 2009, Atherosclerosis.

Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism.

L. Bernier, M. Tremblay, J. Davignon, 2003, Atherosclerosis.

Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state.

P. Hopkins, K. Nakajima, J. Davignon, 2000, Journal of lipid research.

Effect of exercise training on in vitro LDL oxidation and free radical-induced hemolysis: the HERITAGE Family Study.

C. Bouchard, J. Wilmore, D. Rao, 2007, Antioxidants & redox signaling.

Fatty acid composition of tissue phospholipids and prostaglandin excretion in hyperlipidemia induced in rats by implantation of the mammotropic pituitary tumor MtT-F4

Y. Huang, J. Davignon, P. Falardeau, 1983, Lipids.

Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health.

J. Davignon, L. Boulet, C. Marcoux, 2003, The Journal of laboratory and clinical medicine.

Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects.

J. Davignon, L. Mabile, L. Boulet, 2001, The American journal of clinical nutrition.

Effect of methyl linoleate administration on phospholipid fatty acid composition and osmotic fragility of erythrocytes in essential fatty acid deficient rats.

Y. Huang, R. Dufour, J. Davignon, 1983, Journal of the American College of Nutrition.

Most biological effects of zinc deficiency corrected by γ-linolenic acid (18: 3ω6) but not by linoleic acid (18: 2ω6)

D. Horrobin, Y. Huang, S. Cunnane, 1982 .

Quebec Cooperative Study of Friedreich ' s Ataxia Tissue Lipids in Acute Acrylamide Intoxicated Rats

Yung-Sheng Huang, A. Barbeau, J. Davignon, 2014 .

Lecithin: Cholesterol Acyltransferase Activity and Fatty Acid Composition of Erythrocyte Phospholipids in Friedreich's Ataxia

Y. Marcel, A. Barbeau, J. Davignon, 1980, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Fatty Acid Profile of Major Lipid Classes in Plasma Lipoproteins of Patients with Friedreich's Ataxia — Demonstration of a Low Linoleic Acid Content most evident in the Cholesterol-Ester Fraction

A. Barbeau, J. Davignon, Y. Huang, 1979, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

High-density lipoprotein particles in octogenarians.

G. Luc, J. Fruchart, J. Davignon, 1991, Metabolism: clinical and experimental.

Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation 1

J. Ferrières, J. Lambert, J. Davignon, 2014 .

Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.

J. Ferrières, J. Lambert, Jean Lambert, 1995, Circulation.

Apolipoprotein E polymorphism and plasma cholesterol response to probucol.

C. Sing, J. Davignon, D. Bouthillier, 1987, Metabolism: clinical and experimental.

In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia.

D. Rader, R. Gregg, H. Brewer, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Cardioprotective and other emerging effects of statins

J. Davignon, 2004, International journal of clinical practice. Supplement.

Occurrence and biological effects of cholesteryl sulfate on blood platelets.

M. Becchi, J. Davignon, D. Blache, 1995, Biochimica et biophysica acta.

High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes

L. Bernier, E. Bourdon, Evelyne Tarnus, 2009, Journal of cellular biochemistry.

Secreted apolipoprotein E reduces macrophage‐mediated LDL oxidation in an isoform‐dependent way

L. Bernier, J. Davignon, L. Mabile, 2003, Journal of cellular biochemistry.

Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells.

L. Bernier, E. Bourdon, L. Lagrost, 2006, Free radical biology & medicine.

Indications for lipid-lowering drugs

J. Davignon, 2011, European Journal of Clinical Pharmacology.

Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis.

M. Hayden, J. Kastelein, J. Brunzell, 1992, The Journal of biological chemistry.

Most biological effects of zinc deficiency corrected by gamma-linolenic acid (18: 3 omega 6) but not by linoleic acid (18: 2 omega 6).

D. Horrobin, Y. Huang, S. Cunnane, 1982, Atherosclerosis.

Spiromustine: a new agent entering clinical trials

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational New Drugs.

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.

J. Davignon, R. Carmena, G. Roederer, 1993, Metabolism: clinical and experimental.

The effect of insulin on circulating PCSK9 in postmenopausal obese women.

N. Seidah, R. Rabasa-Lhoret, M. Faraj, 2014, Clinical biochemistry.

The interaction of cholesterol absorption and cholesterol synthesis in man.

S. Grundy, J. Davignon, E. H. Ahrens, 1969, Journal of lipid research.

Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.

M. Tremblay, M. Amiot, J. Genest, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.

M. Tremblay, K. Nakajima, J. Davignon, 1998, Atherosclerosis.

Association of apolipoprotein E with α2-macroglobulin in human plasma

M. Tremblay, J. Davignon, J. Cohn, 1998 .

Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.

M. Tremblay, J. Davignon, J. Cohn, 1997, Journal of lipid research.

Short-term response to dietary counseling of hyperlipidemic outpatients of a lipid clinic.

J. Dallongeville, J. Davignon, J. Touchette, 1994, Journal of the American Dietetic Association.

Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.

G. Jerums, J. Kastelein, J. Davignon, 1995, Atherosclerosis.

Beta-blockers and changes in lipoprotein fractions.

P. Bielmann, J. Davignon, G. Leduc, 1980, The New England journal of medicine.

Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I.

M. Tremblay, O. Mamer, J. Genest, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.

Y. Huang, J. LeLorier, J. Davignon, 1977, Archives of internal medicine.

Effect of regular exercise on homocysteine concentrations: the HERITAGE Family Study

C. Bouchard, J. Wilmore, D. Rao, 2006, European Journal of Applied Physiology.

Effect of acute and chronic administration of calcitonin on serum glucose in patients with Paget's disease of bone.

P. Bielmann, J. Davignon, A. Gattereau, 1980, The Journal of clinical endocrinology and metabolism.

Apolipoprotein E and Atherosclerosis

J. Davignon, 2005 .

Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.

J. Genest, Y. Latour, P. Connelly, 1997, The Canadian journal of cardiology.

Apolipoprotein E and atherosclerosis: insight from animal and human studies.

L. Bernier, J. Davignon, L. Mabile, 1999, Clinica chimica acta; international journal of clinical chemistry.

Genetics of lipoprotein disorders.

J. Genest, J. Davignon, 1998, Endocrinology and metabolism clinics of North America.

An intravenous formulation of Δ9‐tetrahydrocannabinol using a non‐ionic surfactant

A. Guarino, J. Davignon, C. Litterst, 1973, The Journal of pharmacy and pharmacology.

Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.D300041-JLR200

M. Tremblay, J. Davignon, J. Cohn, 2004, Journal of Lipid Research.

[Systematic approach to the treatment of hereditary hyperlipidemias].

J. Davignon, S. Lussier‐Cacan, 1980, Revue medicale de Liege.

Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians.

C. Sing, J. Davignon, D. Bouthillier, 1988, Transactions of the American Clinical and Climatological Association.

Advances in lipid-lowering therapy in atherosclerosis.

J. Davignon, 2001, Advances in experimental medicine and biology.

Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.

J. Fruchart, J. Davignon, J. Bard, 1989, Atherosclerosis.

Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond.

J. Davignon, 1997, Evidence-based cardiovascular medicine.

An application of a model for a genotype‐dependent relationship between a concomitant (age) and a quantitative trait(LDL cholesterol)in pedigree data

C. Sing, D. Rao, J. Davignon, 1984, Genetic epidemiology.

G-->A substitution at position -75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels.

J. Davignon, A. Minnich, G. Roederer, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia.

H. Hobbs, D. Russell, M. Brown, 1987, The New England journal of medicine.

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

N. Seidah, H. Thomas, S. Taylor-Robinson, 2015, Journal of hepatology.

Biochemical Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells 1

L. Bernier, J. Davignon, J. Cohn, 2004 .

Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells.

L. Bernier, J. Davignon, J. Cohn, 2004, The Journal of nutrition.

Erythrocyte Membrane Lipids in Fríedreich's Ataxia

D. Shapcott, A. Barbeau, J. Davignon, 1979, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.

M. Tremblay, J. Davignon, J. Cohn, 2001, Metabolism: clinical and experimental.

Canadian Cardiovascular Society Position Statement onFamilial Hypercholesterolemia

D. Gaudet, R. Hegele, J. Brophy, 2014 .

Effect of statin withdrawal on frequency of cardiac events after vascular surgery.

Jeroen J. Bax, J. Kastelein, R. V. van Domburg, 2007, The American journal of cardiology.

Low-density lipoprotein-independent effects of statins.

R. Laaksonen, J. Davignon, 1999, Current opinion in lipidology.

AHA Conference Report on Cholesterol. Drug therapy.

D. Hunninghake, R. Havel, U. Steinbrecher, 1989, Circulation.

Medical management of hyperlipidemia and the role of probucol.

J. Davignon, 1986, The American journal of cardiology.

Drug Therapy Participants

D. Hunninghake, R. Havel, U. Steinbrecher, 2022 .

Usefulness of probucol in treating primary hypercholesterolemia.

J. LeLorier, J. Davignon, M. Enjalbert, 1980, Canadian Medical Association journal.

Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia.

J. Dallongeville, M. Xhignesse, J. Davignon, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Common low-density lipoprotein receptor mutations in the French Canadian population.

H. Hobbs, E. Leitersdorf, J. Davignon, 1990, The Journal of clinical investigation.

Simple, reproducible procedure for selective measurement of lipoprotein lipase and hepatic lipase.

J. Davignon, D. Blache, D. Bouthillier, 1983, Clinical chemistry.

Investigational Drug Information

J. Davignon, J. Cradock, L. Trissel, 1979 .

Enhanced susceptibility of cholesteryl sulfate‐enriched low density lipoproteins to copper‐mediated oxidation

J. Davignon, D. Blache, C. Rodriguez, 1995, FEBS letters.

The relation between triglyceride synthesis in peripheral tissues and postprandial plasma triglyceride levels: preliminary evidence of a role for acylation stimulating protein.

K. Cianflone, J. Dallongeville, J. Davignon, 1992, Clinical and investigative medicine. Medecine clinique et experimentale.

Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.

M. Tremblay, O. Mamer, J. Davignon, 2004, Atherosclerosis.

Homozygous Familial Hypercholesterolemia among French Canadians in Quebec Province

M. Lambert, J. Davignon, P. Lupien, 1989, Arteriosclerosis.

Hyperlipoproteinemia induced by a transplantable pituitary tumor in the rat.

M. Chrétien, C. Gianoulakis, J. Davignon, 1979, Atherosclerosis.

Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings.

C. Sing, J. Davignon, D. Bouthillier, 1983, Journal of lipid research.

Gene set enrichment analysis reveals several globally affected pathways due to SKI-1/S1P inhibition in HepG2 cells.

Satyan Chintawar, Massimo Pandolfo, Reijo Laaksonen, 2007, DNA and cell biology.

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

J. Davignon, G. Dubuc, 2009, Transactions of the American Clinical and Climatological Association.

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.

N. Seidah, E. Levy, Z. Awan, 2013, The Canadian journal of cardiology.

Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians

A. Kessling, A. Chamberland, J. Davignon, 1992, Human Genetics.

Geographic distribution of French‐Canadian low‐density lipoprotein receptor gene mutations in the Province of Quebec

J. Després, D. Gaudet, M. Vohl, 1997, Clinical genetics.

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.

D. Rader, J. Hoeg, M. Grossman, 1995, The Journal of clinical investigation.

Apolipoprotein E limits oxidative stress‐induced cell dysfunctions in human adipocytes

L. Bernier, E. Bourdon, Marjolaine Roche, 2009, FEBS letters.

Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.

M. Tremblay, K. Nakajima, J. Davignon, 1999, Journal of lipid research.

Sources of interindividual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic.

C. Sing, J. Davignon, H. Mailloux, 1988, American journal of human genetics.

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.

M. Naruszewicz, J. Davignon, L. Giroux, 1993, Biochimica et biophysica acta.

Oxidative modification of lipoprotein(a) and the effect of β-carotene

M. Naruszewicz, J. Davignon, E. Selinger, 1992 .

Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.

R. Hegele, B. Reeder, P. Connelly, 1999, The Canadian journal of cardiology.

Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE.

M. Tremblay, J. Davignon, J. Cohn, 1997, Journal of lipid research.

Oxidative stress leads to cholesterol accumulation in vascular smooth muscle cells.

L. Gesquiere, J. Davignon, A. Minnich, 1999, Free radical biology & medicine.

Probucol protects lipoprotein (a) against oxidative modification.

R. Dufour, M. Naruszewicz, J. Davignon, 1992, Metabolism: clinical and experimental.

Interaction of lecithin:cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an alpha 2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance.

J. Genest, J. Davignon, M. Marcil, 2001, The Journal of biological chemistry.

Immunochemical evidence that human apoB differs when expressed in rodent versus human cells Published, JLR Papers in Press, December 16, 2002. DOI 10.1194/jlr.M200413-JLR200

J. Borén, S. Young, T. Innerarity, 2003, Journal of Lipid Research.

Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.

M. Kafrissen, M. Xhignesse, J. Davignon, 1991, Metabolism: clinical and experimental.

Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia.

Y. Marcel, J. Davignon, F. Aubry, 1974, Metabolism: clinical and experimental.

Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients.

M. Naruszewicz, J. Davignon, G. Roederer, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Plasma lipids and lipoprotein patterns in angiographically graded atherosclerosis of the legs and in coronary heart disease.

J. Davignon, M. Lelièvre, S. Lussier‐Cacan, 1977, Canadian Medical Association journal.

An improved radiological method for the evaluation of Achilles tendon xanthomatosis.

H. Lévesque, J. Davignon, M. Langelier, 1973, Canadian Medical Association journal.

Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.

J. Davignon, 1998, The American journal of cardiology.

Severe hypoalphalipoproteinemia induced by a combination of probucol and clofibrate.

J. Davignon, P. Alaupovic, D. Bouthillier, 1986, Advances in experimental medicine and biology.

Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia DOI 10.1194/jlr.M200016-JLR200

L. Bernier, M. Tremblay, O. Mamer, 2002, Journal of Lipid Research.

Expression of apolipoprotein B epitopes in lipoproteins. Relationship to conformation and function.

Y. Marcel, M. Hogue, J. Davignon, 1988, Arteriosclerosis.

Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.

M. Faraj, R. Dufour, J. Davignon, 2017, The Journal of nutrition.

WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects[S]

M. Faraj, J. Davignon, H. Wassef, 2016, Journal of Lipid Research.

White Adipose Tissue Apolipoprotein C-I Secretion in Relation to Delayed Plasma Clearance of Dietary Fat in Humans

M. Faraj, R. Dufour, Alexis Baass, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells.

L. Bernier, J. Davignon, J. Cohn, 2005, Atherosclerosis.

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

B. Patterson, J. Davignon, G. Steiner, 2004, The Journal of clinical endocrinology and metabolism.

Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects DOI 10.1194/jlr.M200055-JLR200

L. Bernier, M. Tremblay, O. Mamer, 2002, Journal of Lipid Research.

Investigational Drug Information

J. Davignon, J. Cradock, L. Trissel, 1978 .

Effect of Atorvastatin on ApoE and ApoC-I Synthesis and Secretion by THP-1 Macrophages

L. Bernier, A. Chamberland, L. Castilho, 2003, Journal of cardiovascular pharmacology.

New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia.

A. Chamberland, J. Davignon, A. Minnich, 1995, Clinical biochemistry.

Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia

C. Sass, J. Davignon, A. Minnich, 1995, Human Genetics.

Pseudo type III dyslipoproteinemia is associated with normal fibroblast lipoprotein receptor activity.

J. LaMarre, J. Davignon, J. Cohn, 1997, Atherosclerosis.

The Genetics of Lipoprotein Disorders

J. Davignon, A. Minnich, J. Cohn, 1996 .

A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect.

A. Kessling, J. Dallongeville, J. Fruchart, 1991, Annals of medicine.

Unexpected Consequences of Deletion of the First Two Repeats of the Ligand-binding Domain from the Low Density Lipoprotein Receptor

J. Davignon, A. Minnich, S. Lussier‐Cacan, 1995, The Journal of Biological Chemistry.

Changes in total and central fat mass after a hypocaloric diet associate with changes of apoC-I in postmenopausal obese women.

R. Rabasa-Lhoret, M. Faraj, D. Prud'homme, 2014, Journal of clinical lipidology.

Identification of a second “French Canadian” LDL receptor gene deletion and development of a rapid method to detect both deletions

A. Kessling, J. Davignon, M. Roy, 1989, Clinical Genetics.

Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.

J. Genest, R. Dufour, J. Davignon, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡

M. Milad, I. McInnes, S. Turner, 2015, Arthritis & rheumatology.

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.M300209-JLR200

M. Tremblay, O. Mamer, J. Davignon, 2003, Journal of Lipid Research.

Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects.

C. Sing, J. Ferrières, J. Davignon, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Cholesteryl sulfate: measurement with beta-sitosteryl sulfate as an internal standard.

Y. Huang, J. Davignon, Y. S. Huang, 1981, Canadian journal of biochemistry.

Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects.

J. Davignon, J. Cohn, C. Marcoux, 1997, Biochimica et biophysica acta.

Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.

F. Kronenberg, J. Davignon, R. Carmena, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Two new large deletions in the low density lipoprotein receptor (LDLR) gene not revealed by PCR-based molecular diagnosis of familial hypercholesterolemia.

L. Bernier, R. Dufour, J. Davignon, 2008, Atherosclerosis.

The lipid content of the diabetic kidney of the rat.

Y. Huang, B. Moulin, J. Davignon, 1984, Canadian journal of physiology and pharmacology.

Colt, multicenter capre open label randomized dose-ranging phase II trial to assess efficacy/safety in patients with mild-to-high hypertriglyceridemia

J. Sampalis, P. Lemieux, R. Dufour, 2014 .

Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.

Lawrence A Leiter, P. Lavin, R. McPherson, 1992, Clinical therapeutics.

A new method for measurement of total plasma PCSK 9 : clinical applications

L. Bernier, N. Seidah, S. Benjannet, 2009 .

Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred

R. Dufour, J. Davignon, L. Boulet, 1992, European Journal of Epidemiology.

The Role of Statins in Dyslipidemia: Making the Difference

Lawrence A Leiter, F. Charbonneau, J. Davignon, 1999 .

Apolipoprotein(a) is present in the triglyceride-rich fraction in type IV hypertriglyceridemia.

J. Dallongeville, J. Davignon, E. Selinger, 1993, Clinical biochemistry.

Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.

J. Dallongeville, J. Davignon, L. Boulet, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins.

M. Kafrissen, M. Xhignesse, J. Davignon, 1990, Fertility and sterility.

Relationship between plasma cholesterol levels and cholesterol esterification in isolated human mononuclear cells.

J. Dallongeville, J. Davignon, S. Lussier‐Cacan, 1990, Life sciences.

Apo E Allele Frequency in Primary Endogenous Hypertriglyceridemia (Type IV) with and without Hyperapobetalipoproteinemia

J. Davignon, S. Lussier‐Cacan, D. Bouthillier, 1985, Arteriosclerosis.

Distribution of apolipoprotein E phenotypes in Friedreich's ataxia

C. Sing, R. Milne, A. Barbeau, 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Plasma Lipoprotein Lipase and Hepatic Lipase Activities in Friedreich’s Ataxia

A. Barbeau, J. Davignon, D. Blache, 1982, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Usefulness of chromic oxide as an internal standard for balance studies in formula-fed patients and for assessment of colonic function.

J. Davignon, E. H. Ahrens, W. Simmonds, 1968, The Journal of clinical investigation.

In vitro factors affecting the concentration of gamma-LpE (gamma-LpE) in human plasma.

M. Tremblay, J. Davignon, J. Cohn, 1998, Journal of Lipid Research.

Association of an exon 3 mutation (Trp66-->Gly) of the LDL receptor with variable expression of familial hypercholesterolemia in a French Canadian family.

E. Levy, M. Lambert, J. Davignon, 1997, Biochemical and molecular medicine.

[Mechanisms of action of statins and their pleiotropic effects].

J. Davignon, L. Mabile, 2001, Annales d'endocrinologie.

Hyperhomocysteinemia induced by folic acid deficiency and methionine load--applications of a modified HPLC method.

P. Durand, J. Davignon, D. Blache, 1996, Clinica chimica acta; international journal of clinical chemistry.

Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures.

J. Poirier, J. Davignon, D. Dea, 1999, Brain research. Molecular brain research.

Diagnosis and Treatment of Hyperlipidemias

J. Davignon, 1985 .

Pharmacokinetics of clofibrate in familial hypercholesterolemia.

J. Davignon, L. Boulet, R. Pichardo, 1977, Atherosclerosis.

Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.

J. Davignon, F. Aubry, Y. Lapierre, 1971, Annals of internal medicine.

Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.

M. Tremblay, K. Weisgraber, J. Davignon, 1995, Journal of lipid research.

of Plasma for

J. Davignon, 2004 .

Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).

D. Gaudet, R. McPherson, G. Fodor, 2005, The Canadian journal of cardiology.

Plasma phospholipids in the different types of primary hyperlipoproteinemia.

Y. Marcel, J. Davignon, C. Noël, 1972, The Journal of laboratory and clinical medicine.

Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.

J. Frohlich, R. Dufour, J. Davignon, 1993, The Canadian journal of cardiology.

Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg13,+ His): association with mild dyslipidemia and double pre-p very low density lipoproteins

M. Tremblay, K. Weisgraber, J. Davignon, 2002 .

Oxidative modification of lipoprotein(a) and the effect of beta-carotene.

M. Naruszewicz, J. Davignon, E. Selinger, 1992, Metabolism: clinical and experimental.

Reply to Letters from Dr Maria Luz Fernandez, Eddie Vos, and Dr Niva Shapira

D. Jenkins, J. Davignon, J. Spence, 2011 .

Biochemical Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells 1

L. Bernier, J. Davignon, J. Cohn, 2004 .

Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a).

J. Davignon, L. Giroux, M. Naruszewicze, 1994, Chemistry and physics of lipids.

A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia

D. Hunninghake, R. Goldberg, E. Nikkilä, 1990 .

Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia.

J. Davignon, C. Roy, S. Lussier‐Cacan, 1986, Clinical and investigative medicine. Medecine clinique et experimentale.

2.W15.1 Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants

J. Davignon, J. Cohn, 1997 .

Apolipoprotein E2(Arg158→Cys) Frequency in a Hyperlipidemic French‐Canadian Population of Apolipoprotein E2/2 Subjects: Determination by Synthetic Oligonucleotide Probes

J. Taylor, R. Mahley, K. Weisgraber, 1989, Arteriosclerosis.

Effects of Ketanserin on Lipids, Lipoproteins, and Plasma Atrial Natriuretic Factor in Patients with Essential Hypertension

P. Bielmann, J. Davignon, J. Gutkowska, 1990, Journal of clinical pharmacology.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Raimund Erbel, Jean-Claude Tardif, Paul Schoenhagen, 2006, JAMA.

Lipoprotein lipase gene mutations in coronary artery disease.

J. Genest, J. Davignon, A. Minnich, 1998, The Canadian journal of cardiology.

Net esterification in vitro of plasma cholesterol in human primary hyperlipidemia

Y. Marcel, J. Davignon, H. D. Fabien, 1971, Lipids.

Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma.

F. Mailly, J. Davignon, A. C. Nestruck, 1990, Journal of lipid research.

Round table discussion: practical issues in the management of dyslipidaemic patients.

W. Castelli, G. Assmann, J. Betteridge, 1996, Atherosclerosis.

Association of apolipoprotein E with alpha2-macroglobulin in human plasma.

M. Tremblay, J. Davignon, J. Cohn, 1998, Journal of lipid research.

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

R. Krauss, S. Grundy, R. Mahley, 1990, Journal of lipid research.

Time to take a stance on cholesterol and lipoproteins.

J. Davignon, J. A. Little, 1988, The Canadian journal of cardiology.

Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels.

L. Pérusse, J. Davignon, N. Robitaille, 1996, Human biology.

Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Y. Marcel, J. Davignon, R. Milne, 1984, The Journal of clinical investigation.

Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: gender-specific effects

C. Sing, J. Ferrières, J. Davignon, 1994 .

Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis.

J. Dallongeville, J. Davignon, S. Lussier‐Cacan, 1992, Journal of lipid research.

A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

T. Fleming, L. Kvols, J. Rubin, 1982, The New England journal of medicine.

A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

T. Fleming, L. Kvols, J. Rubin, 1982, The New England journal of medicine.

Pharmaceutical assessment of amygdalin (Laetrile) products.

J. Davignon, L. Trissel, L. M. Kleinman, 1978, Cancer treatment reports.

Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component.

R. Percival-Smith, D. Farquhar, J. Davignon, 1990, Contraception.

Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports.

M. Xhignesse, J. Davignon, G. Roederer, 1988, JAMA.

Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain.

Y. Christen, J. Poirier, J. Davignon, 2001, Brain research. Molecular brain research.

Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype.

Y. Christen, J. Poirier, R. Quirion, 1999, Free radical biology & medicine.

The role of potatoes and potato components in cardiometabolic health: A review

J. Davignon, A. Kurilich, C. Mcgill, 2013, Annals of medicine.

Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate.

J. Selhub, J. Genest, Y. Latour, 1995, The American journal of cardiology.

Tiazofurin: A new antitumor agent

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational new drugs.

Plasma Lipids and Lipoproteins in Friedreich's Ataxia and Familial Spastic Ataxia — Evidence for an Abnormal Composition of High Density Lipoproteins

J. Bouchard, Y. Huang, A. Barbeau, 1978, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Residual macrovascular risk in 2013: what have we learned?

A. Gotto, D. Rader, M. Krempf, 2014, Cardiovascular Diabetology.

Molecular Analysis of Human Prorenin Prosegment Variants in Vitro and in Vivo(*)

E. Schiffrin, J. Davignon, G. Thibault, 1995, The Journal of Biological Chemistry.

Determination of Δ9-tetrahydrocannabinol in pharmaceutical vehicles by high-performance liquid chromatography vehicles by high-performance liquid chromatography

J. Davignon, J. Cradock, K. Flora, 1981 .

Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalization by aspirin.

J. Davignon, D. Blache, D. Bouthillier, 1992, Atherosclerosis.

Beneficial Cardiovascular Pleiotropic Effects of Statins

J. Davignon, 2004, Circulation.

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.

D. Sprecher, W. Insull, H. Schrott, 2001, Atherosclerosis.

Lipid and lipoprotein secretion following portacaval shunt in swine.

Y. Marcel, J. Davignon, A. C. Nestruck, 1978, Atherosclerosis.

The effect of portacaval shunt on plasma lipids and lipoproteins in swine.

Y. Marcel, J. Davignon, S. Lussier‐Cacan, 1977, Biochimica et biophysica acta.

Studies on the in vitro production of corticosteroids by adrenal glands from normotensive individuals and hypertensive patients.

J. Davignon, J. Genest, W. Nowaczynski, 1962, Canadian journal of biochemistry and physiology.

Plasma cholesterol esterification in normal and hyperlipoproteinemic subjects.

Y. Marcel, J. Davignon, H. D. Fabien, 1973, Canadian journal of biochemistry.

Ongoing Clinical Trials of the Pleiotropic Effects of Statins

Lawrence A Leiter, J. Davignon, 2005, Vascular health and risk management.

PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia: A Cross-Sectional Cohort Study

R. Dufour, Alexis Baass, J. Davignon, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate.

M. Lafortune, J. Davignon, F. Aubry, 1971, Revue canadienne de biologie.

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

P. Barter, M. Kaouache, L. Joseph, 2009, Archives of internal medicine.

Halofenate versus clofibrate in the management of true diabetes insipidus.

J. Davignon, M. Verdy, A. Gattereau, 1974, Canadian Medical Association journal.

Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

L. Bernier, A. Prat, N. Seidah, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation.

C. Sing, J. Davignon, J Davignon, 1985, American journal of human genetics.

Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools

L. Shaw, F. Crea, J. Schulz-Menger, 2007, Journal of internal medicine.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte‐specific low‐density lipoprotein receptor degradation and critical role in mouse liver regeneration

Annik Prat, A. Prat, N. Seidah, 2008, Hepatology.

Guanethidine administration in 28 hypertensive patients.

P. Biron, G. Pigeon, J. Davignon, 1960, Canadian Medical Association journal.

Apolipoprotein E, synaptic plasticity and Alzheimer's disease.

J. Poirier, J. Davignon, A. Minnich, 1995, Annals of medicine.

Expression of gamma-IFN responsive genes in scavenger receptor over-expressing monocytes is associated with xanthomatosis.

A. Chamberland, J. Davignon, J. Davignon, 1998, Atherosclerosis.

Current and future treatment of hyperlipidemia: the role of statins.

M. Farnier, J. Davignon, 1998, The American journal of cardiology.

Apolipoprotein E polymorphism and Alzheimer's disease

S. Gauthier, J. Poirier, S. Gauthier, 1993, The Lancet.

Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain

Y. Christen, J. Poirier, J. Davignon, 2000, Neurobiology of Disease.

Impairment of Serum Albumin Synthesis by HEPG 2 Cells Induced − Involvement of Oxysterols and Lysophosphatidylcholine in the Oxidized LDL

L. Bernier, E. Bourdon, J. Davignon, 2000 .

Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects.

M. Hayden, J. Genest, J. Davignon, 1996, Journal of lipid research.

Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a "founder effect".

J. Davignon, J Davignon, M Roy, 1993, The American journal of cardiology.

Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins.

J. Davignon, J. Cohn, C. Marcoux, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Triglyceride-rich Remnant Lipoproteins Detection, Quantification, and Characterization of Potentially Atherogenic

J. Davignon, J. Cohn, C. Marcoux, 2022 .

Triglycerides: a risk factor for coronary heart disease.

J. Davignon, J. Cohn, 1996, Atherosclerosis.

Parallel biochemical and histochemical studies of an adrenocortical adenoma from a patient with primary aldosteronism.

J. Davignon, J. Genest, W. Nowaczynski, 1961, Acta endocrinologica.

Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health.

C. Sing, A. Kessling, M. Xhignesse, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Dietary cholesterol and egg yolks: not for patients at risk of vascular disease.

J. Spence, D. Jenkins, J. Davignon, 2010, The Canadian journal of cardiology.

Failure to isolate cortisol from a pheochromocytoma.

J. Genest, J. Davignon, G. Tremblay, 1960, The Journal of clinical endocrinology and metabolism.

Egg yolk consumption and carotid plaque.

J. Spence, D. Jenkins, J. Davignon, 2012, Atherosclerosis.

β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons

J. Poirier, J. Davignon, D. Dea, 1998, Journal of neurochemistry.

Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent

Charles Ramassamy, Judes Poirier, J. Poirier, 1999, Brain Research.

Gene set enrichment analyses revealed several affected pathways in Niemann-pick disease type C fibroblasts.

L. Bernier, M. Pandolfo, R. Laaksonen, 2007, DNA and cell biology.

Ongoing clinical trials of the pleiotropic effects

Lawrence A Leiter, J. Davignon, 2005 .

Pleiotropic effects of pitavastatin

J. Davignon, 2011, British journal of clinical pharmacology.

Egg yolk consumption, smoking and carotid plaque: reply to letters to the Editor by Sean Lucan and T Dylan Olver et al.

J. Spence, D. Jenkins, J. Davignon, 2013, Atherosclerosis.

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

A. Sorisky, T. Ooi, L. Leiter, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

J. Isaacsohn, R. Goldstein, V. Miller, 1996, JAMA.

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

A. Prat, N. Seidah, R. Parker, 2012, PloS one.

Indications for lipid-lowering drugs

J. Davignon, 2005, European Journal of Clinical Pharmacology.

Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.

M. Hanefeld, D. Hunninghake, W. Insull, 1998, The American journal of cardiology.

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

J. Poirier, M. Farlow, D. Lahiri, 1998, Neurology.

Genetic structure and the search for genotype-phenotype relationships: an example from disequilibrium in the Apo B gene region.

C. Sing, A. Kessling, K. Zerba, 1991, Genetics.

Estimation of Hardy-Weinberg and pairwise disequilibrium in the apolipoprotein AI-CIII-AIV gene cluster.

C. Sing, A. Kessling, J. Davignon, 1991, American journal of human genetics.

genotype and gender of the subjects with Alzheimer ' s disease Treatment outcome of tacrine therapy depends on apolipoprotein

M. Farlow, D. Lahiri, S. Hui, 2007 .

HMG-CoA reductase inhibitors: a look back and a look ahead.

R. Dufour, J. Davignon, M. Montigny, 1992, The Canadian journal of cardiology.

Psychotropic drugs as potential antitumor agents: a selective screening study.

J. Davignon, J. Driscoll, F. R. Quinn, 1978, Cancer treatment reports.

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

N. H. Nguyen, P. Théroux, J. Genest, 2000, Journal of cardiovascular pharmacology.

Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status, and ApoE phenotype.

J. Davignon, J. Cohn, L. Fortin, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Postprandial Lipoproteins and their Relationship to Atherosclerosis and Thrombosis

J. Davignon, J. Cohn, 1996 .

Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization.

J. Frohlich, J. Genest, J. Davignon, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects.

P. Talmud, M. Xhignesse, F. Mailly, 1991, Journal of lipid research.

Diet, Atherosclerosis, and Endothelial Dysfunction

J. Davignon, J. Cohn, 2003 .

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians.

C. Sing, J. Davignon, M. B. Haviland, 1995, American journal of medical genetics.

ApoE phenotype influences plasma ASP in hyperapoB subjects.

K. Cianflone, B. Gilfix, J. Davignon, 2003, Atherosclerosis.

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

M. Tremblay, O. Mamer, J. Davignon, 2003, Journal of lipid research.

Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.

M. Tremblay, O. Mamer, P. Barrett, 2000, Journal of lipid research.

Apolipoprotein E and Low‐Density Lipoprotein Binding and Internalization in Primary Cultures of Rat Astrocytes: Isoform‐Specific Alterations

J. Poirier, J. Davignon, D. Dea, 1996, Journal of neurochemistry.

Cladistic analysis of the apolipoprotein AI‐CIH‐AIV gene cluster using a healthy French Canadian sample. I. Haploid analysis

C. Sing, A. Kessling, J. Davignon, 1995, Annals of human genetics.

The antioxidant effects of statins

R. Jacob, R. Mason, J. Davignon, 2004, Coronary artery disease.

Interaction of Two Lipid Disorders in a Large French‐Canadian Kindred

C. Sing, J. Davignon, P. Moll, 1983, Arteriosclerosis.

Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids.

Y. Marcel, J. Davignon, P. Douste-Blazy, 1982, Annals of internal medicine.

The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis

N. Seidah, J. Davignon, G. Dubuc, 2010, Current atherosclerosis reports.

Clearance of plasma proprotein convertase subtilisin/kexin 9 by low-density lipoprotein apheresis.

N. Seidah, J. Davignon, P. Duell, 2014, Circulation research.

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.

E. Levy, M. Tremblay, J. O'Loughlin, 2009, Clinical chemistry.

A new method for measurement of total plasma PCSK9: clinical applications

L. Bernier, N. Seidah, S. Benjannet, 2010, Journal of Lipid Research.

Characterization of inherited scavenger receptor overexpression and abnormal macrophage phenotype in a normolipidemic subject with planar xanthomas.

C. Giry, J. Davignon, A. Minnich, 1996, Journal of lipid research.

Dapsone-induced methemoglobinemia in a patient with P. carinii pneumonia and AIDS.

J. Davignon, G. Roederer, D. Bouthillier, 1987 .

Roentgenological evaluation of Achilles-tendon xanthomatosis.

H. Lévesque, J. Davignon, A. Gattereau, 1971, Lancet.

Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia

M. Lambert, P. Lupien, S. Moorjani, 1993, The Lancet.

Role of zinc in linoleic acid desaturation and prostaglandin synthesis.

D. Horrobin, Y. Huang, S. Cunnane, 1981, Progress in lipid research.

Apolipoprotein E and atherosclerosis: beyond lipid effect.

J. Davignon, Jean Davignon, 2004, Arteriosclerosis, thrombosis, and vascular biology.

(Arch. Intern. Med., 137:1429-1434)Diet and probucol in lowering cholesterol concentrations

J. LeLorier, J. Davignon, Y. S. Huang, 1977 .

Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor.

K. Cianflone, M. Bilodeau, J. Davignon, 1990, Metabolism: Clinical and Experimental.

Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones.

A. Kessling, A. Chamberland, M. Xhignesse, 1992, American journal of human genetics.

Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent.

A. Kessling, C. Giry, J. Davignon, 1995, Journal of lipid research.

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

A. von Eckardstein, G. Assmann, D. Müller-Wieland, 2016, European journal of preventive cardiology.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

R. McPherson, J. Bonnet, A. Tedgui, 2008, Clinical therapeutics.

Identification of a &ggr;-Interferon-Responsive Element in the Promoter of the Human Macrophage Scavenger Receptor A Gene

L. Bernier, J. Davignon, T. Grewal, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Effect of fenofibrate treatment on type III hyperlipoproteinemia.

J. Fruchart, C. Fiévet, J. Davignon, 1987, The American journal of medicine.

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.

M. Hayden, R. Hegele, J. Little, 1994, The American journal of cardiology.

Quebec Cooperative Study of Friedreich ' s Ataxia Tissue Lipids in Acute Acrylamide Intoxicated Rats

A. Barbeau, J. Davignon, P. Wong, 2014 .

Atherosclerosis X : proceedings of the 10th International Symposium on Atherosclerosis, Montréal, October 9-14, 1994

F. P. Woodford, J. Davignon, S. Siderman, 1995 .

ACAT activity in freshly isolated human mononuclear cell homogenates from hyperlipidemic subjects.

J. Dallongeville, J. Davignon, S. Lussier‐Cacan, 1992, Metabolism: clinical and experimental.

EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs.

J. Beijnen, J. Davignon, J. Slack, 1988, European journal of cancer & clinical oncology.

Involvement of Oxysterols and Lysophosphatidylcholine in the Oxidized LDL–Induced Impairment of Serum Albumin Synthesis by HEPG2 Cells

L. Bernier, E. Bourdon, J. Davignon, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Macrophage Scavenger Receptor A Gene Responsive Element in the Promoter of the Human −-Interferon γ Identification of a Print

L. Bernier, J. Davignon, T. Grewal, 2001 .

Heroin: Stability and formulation approaches

J. Davignon, J. Cradock, G. Poochikian, 1983 .

[Phenotype of apolipoprotein E, hyperlipidemia and atherosclerosis].

J. Davignon, G. Roederer, 1988, L'union medicale du Canada.

Impact of a common mutation of the LDL receptor gene, in French‐Canadian patients with familial hypercholesterolemia, on means, variances and correlations among traits of lipid metabolism

C. Sing, J. Davignon, M. Roy, 1995, Clinical genetics.

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.

L. Bernier, N. Seidah, J. Mayne, 2011, Clinical chemistry.

Apolipoprotein B‐48 and B‐100 Very Low Density Lipoproteins: Comparison in Dysbetalipoproteinemia (Type III) and Familial Hypertriglyceridemia (Type IV)

Y. Marcel, J. Davignon, R. Milne, 1985, Arteriosclerosis.

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

L. Bernier, J. Mayne, M. Chrétien, 2013, Lipids in Health and Disease.

Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.

J. Davignon, R. Carmena, A. Minnich, 2000, Atherosclerosis.

(Can. J. Neurol. Sci., 06:291-294)Erythrocyte membrane lipids in Friedreich's ataxia

D. Shapcott, A. Barbeau, J. Davignon, 1979 .

Plasma Cholesteryl Sulfate in Friedreich's ataxia

R. Dufour, A. Barbeau, J. Davignon, 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Quebec Cooperative Study of Friedreich ' s Ataxia Plasma Lipids and Lipoproteins in Friedreich ' s Ataxia and Familial Spastic Ataxia — Evidence for an Abnormal Composition of High Density Lipoproteins

J. Bouchard, Y. Huang, A. Barbeau, 2014 .

Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a

J. Poirier, D. Lahiri, S. Hui, 1996, Annals of the New York Academy of Sciences.

Apolipoprotein E Uptake is Increased by Beta-Amyloid Peptides and Reduced by Blockade of the LDL Receptor

J. Poirier, J. Davignon, D. Dea, 1996 .

Advances in drug treatment of dyslipidemia: focus on atorvastatin.

J. Davignon, 1998, The Canadian journal of cardiology.

A PCSK9 variant and familial combined hyperlipidaemia

L. Bernier, A. Munnich, C. Boileau, 2008, Journal of Medical Genetics.

Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect.

A. Kessling, J. Davignon, M. Roy, 1996, Atherosclerosis.

Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits.

J. Selhub, M. Xhignesse, J. Genest, 1996, The American journal of clinical nutrition.

Pro‐oxidant effects of 7‐hydroperoxycholest‐5‐en‐3β‐ol on the copper‐initiated oxidation of low density lipoprotein

J. Davignon, D. Blache, C. Rodriguez, 1995, FEBS letters.

Risks for hyperlipidemia.

J. Davignon, A. C. Nestruck, 1986, Cardiology clinics.

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.

A. Gotto, A. Keech, S. Grundy, 1998, The American journal of cardiology.

A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians.

M. Hayden, P. Julien, J. Brunzell, 1991, The New England journal of medicine.

Fish-oil supplementation reduces Ip(a) concentrations in type III dysbetalipoproteinemia.

J. Dallongeville, J. Davignon, S. Lussier‐Cacan, 1992, Clinical chemistry.

Lipolytic and hypocalcemic effects of sheep beta-lipotropic hormone.

M. Chrétien, J. Davignon, C. Gilardeau, 1970, Canadian journal of physiology and pharmacology.

Formulation of three nitrosoureas for intravenous use.

J. Davignon, J. Cradock, H. Wood, 1973, Cancer chemotherapy reports. Part 3.

Primary Hyperlipidemias: An Atlas Of Investigation And Diagnosis

R. Dufour, J. Davignon, 2007 .

Prospects for drug therapy for hyperlipoproteinaemia.

J. Davignon, 1995, Diabete & metabolisme.

Effect of indomethacin treatment on prostaglandin excretion and tissue phospholipid fatty acid composition in rats bearing mammotropic pituitary tumor, MtT-F4.

Y. Huang, J. Davignon, P. Falardeau, 1986, Prostaglandins, leukotrienes, and medicine.

Common low-density lipoprotein receptor mutations in the French Canadian population.

H. Hobbs, E. Leitersdorf, J. Davignon, 1990, The Journal of clinical investigation.

[Lipoproteins and lipid transport].

J. Davignon, 1968, L'union medicale du Canada.

A new method for measurement of total plasma PCSK9: clinical applications

L. Bernier, N. Seidah, S. Benjannet, 2010, Journal of Lipid Research.

Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection – Reduced production or increased LDL clearance?

N. Seidah, J. Davignon, M. Bassendine, 2010 .

Dissolution and absorption of the antineoplastic agent ellipticine.

J. Davignon, A. Rahman, J. Cradock, 1978, Journal of pharmaceutical sciences.

Development of Hyperlipidemia Associated with Increased Lipolytic Response of Isolated Adipose Tissue Cells Following Prolonged Stimulation by an Ectopic Pituitary Tumor*

M. Chrétien, C. Gianoulakis, J. Davignon, 1978, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i)

P. Amarenco, J. Fruchart, K. Al-Rubeaan, 2014 .

Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health.

C. Sing, A. Kessling, M. Xhignesse, 1999, American journal of epidemiology.

Apolipoprotein E limits oxidative stress‐induced cell dysfunctions in human adipocytes

L. Bernier, E. Bourdon, Marjolaine Roche, 2009, FEBS letters.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

D. Gaudet, B. McCrindle, R. Hegele, 2014, The Canadian journal of cardiology.

Severe oily ichthyosis in monozygotic twins mimicking Chanarin-Dorfman syndrome but not associated with a mutation of the CGI58 gene.

L. Bernier, R. Dufour, J. Davignon, 2006, Archives of dermatology.

White Adipose Tissue Apolipoprotein C-I Secretion in Relation to Delayed Plasma Clearance of Dietary Fat in Humans

M. Faraj, R. Dufour, J. Davignon, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Mechanism for National Distribution of Δ9‐Tetrahydrocannabinol (NSC‐134454)

J. Davignon, D. Abraham, KENNETH R. Pina, 1981 .